Partial GABAA Modulators for Benzodiazepine Misuse Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for benzodiazepine misuse and/or use disorder are ineffective and come with significant side effects, including increased abuse potential, motor coordination deficits, appetite suppression, respiratory suppression, and the risk of precipitating withdrawal.
Innovation Solution
Development of compounds with mixed partial modulator and antagonist profiles that target GABAA receptors, capable of reducing anxiety while suppressing the effects of benzodiazepines without introducing new abuse potential or significant side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional benzodiazepines are used to treat anxiety, then anxiolytic effects are achieved, but abuse potential and dependence risk increase
Solution Approach 1:
The patent modifies the pharmacological parameters of GABAA receptor ligands by developing partial modulators with reduced intrinsic efficacy compared to full agonists. This parameter change allows the compounds to produce anxiolytic effects while significantly reducing positive reinforcing effects and abuse potential, directly resolving the contradiction between therapeutic efficacy and abuse risk
Solution Approach 2:
The patent applies local quality by creating compounds with selective action at different GABAA receptor subtypes. The partial modulators exhibit preferential binding to specific subunit compositions (e.g., α2/α3-containing receptors) that mediate anxiolytic effects while having minimal impact on subtypes associated with sedation and abuse reinforcement, thus achieving targeted therapeutic effect with reduced harmful properties
2Reliability
If off-label benzodiazepines or barbiturates are used to treat benzodiazepine misuse, then some therapeutic effect is achieved, but toxicity and abuse liability increase
Solution Approach 1:
The patent introduces partial modulators as intermediary compounds that occupy the GABAA receptor binding site without producing full agonist effects. These intermediaries act as functional antagonists to benzodiazepines by competing for binding while producing minimal activation, thereby blocking the effects of abused benzodiazepines without introducing the severe toxicity associated with barbiturates or other off-label treatments
Solution Approach 2:
The patent converts the harmful property of GABAA receptor activation (which produces both therapeutic anxiolytic effects and abuse potential) into a beneficial treatment approach. By using partial modulators that produce sub-maximal activation, the therapy leverages the same receptor system to block benzodiazepine effects while avoiding the toxicity of alternative treatments like barbiturates
3Reliability
If full agonist benzodiazepines are used to provide anxiolytic effects, then anxiety is reduced, but motor coordination deficits and respiratory suppression occur
Solution Approach 1:
The patent changes the efficacy parameter of GABAA receptor ligands from full agonism to partial modulation. This parameter change results in compounds that produce sufficient anxiolytic effects through preferential binding to specific receptor subtypes while producing minimal sedative and motor coordination deficits, as the partial modulators do not produce the same degree of generalized GABAA receptor activation as full agonists
Solution Approach 2:
The patent achieves selective anxiolytic effects with minimal side effects by targeting specific GABAA receptor subtypes (particularly α2/α3-containing receptors) that are more involved in anxiety regulation rather than motor control. This local quality approach allows the partial modulators to produce therapeutic effects while sparing the neural circuits responsible for motor coordination and respiratory control
4Object-affected harmful factors
If antagonist compounds are used to block benzodiazepine effects, then abuse potential is reduced, but withdrawal precipitation occurs
Solution Approach 1:
The patent applies partial action by using partial modulators that produce sub-maximal activation of GABAA receptors. These compounds occupy the binding site and compete with benzodiazepines but produce only partial agonist effects, thereby blocking the reinforcing properties of full agonists while avoiding the severe withdrawal precipitation caused by complete antagonists. The partial activation is sufficient to reduce abuse potential but insufficient to trigger severe withdrawal
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively treat benzodiazepine misuse and/or use disorder by providing anxiolytic effects with reduced positive reinforcing effects, suppressing benzodiazepine effects independently of sedative or motor effects, and avoiding withdrawal precipitation, all without substantial motor, appetite, or respiratory side effects.
Implementation Method 1
compounds with mixed partial modulator and antagonist profiles that target GABAA receptors
Data Source
AI summary
Disclosed are compositions and methods for treating benzodiazepine misuse and/or use disorder. A method of treating benzodiazepine misuse and/or use disorder includes administering to a subject in need thereof of an effective amount of a compound provides both partial modulator and antagonist effects at GABAA receptors.